Can a targeted antibody calm severe eczema?
Disease control
Not yet recruiting
This first-in-human trial evaluates BYN-001, an antibody designed to block IL-25, a protein linked to atopic dermatitis (eczema). The study first tests the drug in healthy volunteers to assess safety and how it moves through the body, then in people with moderate to severe eczema…
Phase: PHASE1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC